4-(2-methyl-quinolin-4-ylmethoxy)-N-[2-(5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-ethyl]-benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(2-methyl-quinolin-4-ylmethoxy)-N-[2-(5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-ethyl]-benzamide
• 英文别名: 4-((2-methylquinolin-4-yl)methoxy)-N-(2-(5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)ethyl)benzamide；4-[(2-methylquinolin-4-yl)methoxy]-N-[2-(5-sulfanylidene-1,2-dihydro-1,2,4-triazol-3-yl)ethyl]benzamide
• 化学式: C₂₂H₂₁N₅O₂S
• 分子量: 419.507
• InChiKey: MEWQGNPVNKWBSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 sodium hydroxide 作用下， 生成 4-(2-methyl-quinolin-4-ylmethoxy)-N-[2-(5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-ethyl]-benzamide
  参考文献：
  名称：

  Synthesis and structure–activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors

  摘要：

  A novel series of TNF-alpha converting enzyme (TACE) inhibitors which are non-hydroxamate have been discovered. These compounds use a triazolethione moiety as the zinc binding ligand and exhibit IC(50) values from 1.5 to 100 nM in a porcine TACE assay. They also have excellent selectivities over other MMPs.(c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.100

文献信息

• Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
  申请人：——

  公开号：US20040116491A1

  公开（公告）日：2004-06-17

  The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R 11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.

  本申请描述了式 (I) 的新型海因衍生物： 1 或其药学上可接受的盐或原药形式，其中 A、L 和 R 11 可用作基质金属蛋白酶 (MMP)、TNF-&agr; 转换酶 (TACE)、凝集素酶或其组合的抑制剂。
• EP1558581A4
  申请人：——

  公开号：EP1558581A4

  公开（公告）日：2007-07-25
• TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：EP1558581A2

  公开（公告）日：2005-08-03
• US7074810B2
  申请人：——

  公开号：US7074810B2

  公开（公告）日：2006-07-11
• [EN] TRIAZOLONE AND TRIAZOLETHIONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME<br/>[FR] DERIVES DE LA TRIAZOLONE ET DE LA TRIAZOLETHIONE, INHIBITEURS DES METALLOPROTEINASES DE MATRICES ET/OU DE L'ENZYME DE CONVERSION DU TNF DOLLAR G(A)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2004032846A2

  公开（公告）日：2004-04-22

  The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-a converting enzyme (TACE), aggrecanase, or a combination thereof.